

Apollo Hospitals Enterprise Limited

Corporate Identity Number : L85110TN1979PLC008035

Regd. Office : No. 19 Bishop Gardens, Raja Annamalaiapuram, Chennai - 28, Tamil Nadu

Tel. +91-44-28290956, Fax: +91-44-28290956

Email: investor.relations@apollohospitals.com, Website : www.apollohospitals.com



Extract of Statement of Audited Financial Results for the Three Months and Year Ended March 31, 2020

(Rs. in Lakhs, except per share data)

Particulars	Standalone				Consolidated			
	Three months ended 31/03/2020	Preceding three months ended 31/12/2019	Corresponding three months ended 31/03/2019	Year ended 31/03/2020	Previous year ended 31/03/2019	Three months ended 31/03/2020	Preceding three months ended 31/12/2019	Corresponding three months ended 31/03/2019
Total Income from Operations (net)	2,57,138	2,53,251	2,16,926	9,80,534	8,34,890	2,92,638	2,92,140	2,51,126
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	11,123	14,564	11,999	51,801	46,247	8,534	14,530	11,190
Net Profit / (Loss) for the period (before Tax, after Exceptional and/or Extraordinary Items)	27,558	14,564	11,999	68,236	46,247	28,364	14,530	11,190
Net profit / (loss) for the period after tax (after Exceptional and Extraordinary Items)	20,560	9,475	7,668	47,025	30,275	20,960	8,996	7,280
Total Comprehensive Income for the period (comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	20,611	9,395	7,127	47,100	27,364	21,404	8,901	6,798
Paid up Equity Share Capital (Face value of Rs.5/- each)	6,956	6,956	6,956	6,956	6,956	6,956	6,956	6,956
Other Equity				3,91,897	3,81,384			3,26,209
Earnings Per Share of Rs. 5/- each Basic	*14.78	*6.81	*5.51	33.80	21.76	*15.77	*6.62	*5.87
Diluted	*14.78	*6.81	*5.51	33.80	21.76	*15.77	*6.62	*5.87
Debt Equity Ratio				0.82	0.88			
Debt Service Coverage Ratio				2.92	2.45			
Interest Service Coverage Ratio				4.27	4.24			
Networth				3,85,570	3,70,057			
Paid up Debt Capital				50,000	70,000			
Debt Redemption Reserve				12,500	17,500			
Capital Redemption Reserve				600	600			

* Not Annualised

Notes:

- The above is an extract of the detailed format of financial results (both standalone and consolidated) for the three months and year ended March 31, 2020 filed with stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the stock exchange websites www.nseindia.com and www.bseindia.com and also the company's website www.apollohospitals.com.
- The standalone financial information of Apollo Hospitals Enterprise Limited ("the Company") for the three months and year ended March 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on June 24, 2020 and June 25, 2020 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three months ended March 31, 2020 and have expressed an unmodified audit opinion on the financial results for the year ended March 31, 2020. These standalone financial results have been extracted from the standalone financial information. The statutory auditors have not issued a separate limited review report on the results for the quarter ended March 31, 2019.
- The consolidated financial information of Apollo Hospitals Enterprise Limited ("the Company") for the three months and year ended March 31, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on June 24, 2020 and June 25, 2020 respectively. The statutory auditors, Deloitte Haskins & Sells LLP have expressed an unmodified review conclusion on the financial results for the three months ended March 31, 2020 and have expressed an unmodified audit opinion on the financial results for the year ended March 31, 2020. These consolidated financial results have been extracted from the consolidated financial information. The statutory auditors have not issued a separate limited review report on the consolidated results for the quarter ended March 31, 2019.
- The standalone financial results for the three months ended March 31, 2020 and March 31, 2019 are the balancing figures between the audited standalone figures for the respective years ended on those dates and the unaudited year to date standalone figures for the periods ending December 31, 2019 and December 31, 2018 respectively, which were subject to limited review.
- The consolidated financial results for the three months ended March 31, 2020 are the balancing figures between the audited consolidated figures for the year ended March 31, 2020 and the unaudited year to date consolidated figures for the period ending December 31, 2019, which was subject to limited review. The consolidated results for the three months ended March 31, 2019 are approved by the Company's Board of Directors, but have not been subjected to a limited review by the statutory auditors.
- For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52(4) of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the Stock Exchanges (BSE and NSE) and can be accessed on the URL (www.bseindia.com and www.nseindia.com)
- The Board of Directors recommended a final dividend of Rs. 2.75 per share (55% of face value of Rs.5/- per share) for the financial year ended 31st March 2020, on the paid up equity shares of the Company. The dividend will be paid after approval of the shareholders at the ensuing Annual General Meeting. The Company declared an interim dividend of Rs. 3.25 (65%) per equity share of face value of Rs. 5/- each and the said dividend was paid to the shareholders on 5th March 2020 whose names appeared in the register of members as on 26th February 2020, being the record date fixed for this purpose. Hence, the total dividend for the year FY 2019-20 works out to Rs. 6/- per share (120% of face value of Rs.5/- per share).
- The listed non-convertible Debentures of the Company aggregating to Rs. 50,000 lakhs as on March 31, 2020 are secured by way of first mortgage / charge on the company's properties and the asset cover thereof exceeds hundred percent of the principal amount of the debentures
- The Board of Directors at their meeting held on November 14, 2018 had approved a Scheme of Arrangement ("the Scheme") between Apollo Hospitals Enterprise Limited ("AHEL") and Apollo Pharmacies Limited ("APL") and their respective shareholders in accordance with the provisions of Sections 230 to 232 of the Companies Act, 2013, for the transfer of the front-end retail pharmacy business carried out in the standalone pharmacy segment to APL by way of slump sale, subject to necessary approvals by stock exchanges, shareholders, the National Company Law Tribunal and all other requisite regulatory authorities. The Company received no objection letters from National Stock Exchange of India Limited and BSE Limited. Further, the Company obtained approvals from the Competition Commission of India (CCI) and from the equity shareholders in October 2019. The petition seeking sanction of the Scheme, is pending before the National Company Law Tribunal (NCLT). The Scheme would become effective upon filing of the Scheme as sanctioned by the NCLT, with the Registrar of Companies.
- The Board of Directors at their meeting held on February 13, 2020 approved the proposal for merger of the following wholly owned subsidiary companies with the Company:
 - Apollo Home Healthcare (India) Limited and
 - Western Hospitals Corporation Private Limited
- The Company is in the process of submitting an application to the National Company Law Tribunal (NCLT), Chennai seeking exemption for convening the shareholders'/creditors meeting of the Company. The Company, after meeting the closing conditions for the sale of investments in an associate, Apollo Munich Health Insurance Company Limited (AMHI) to Housing Development Finance Corporation Limited, in the quarter ended March 31, 2020 has recognised the sale and recorded a profit of Rs. 19,646 lakhs (net of transaction costs and after considering indemnity related deductions), which has been disclosed under Exceptional Items.
- The Company has impaired its equity investment and advance receivable in its subsidiary Apollo Lavasa Health Corporation Limited, aggregating to Rs. 3,210 lakhs disclosed under Exceptional Items consequent to continuing constraints faced at the Lavasa Hill Station coupled with further uncertainties arising out of the COVID-19 pandemic.
- The Management has considered the possible effects if any that may result from the pandemic relating to COVID-19 on the impairment of carrying amounts of cash generating units (CGUs), trade receivables, investments, in developing the assumptions and estimates relating to the uncertainties as at the Balance Sheet date in relation to the recoverable amounts of these assets, management has considered the overall economic conditions prevailing as at the date of approval of these financial results, and has used internal and external sources of information to the extent determined by it. The actual outcome of these assumptions and estimates may vary in future due to the impact of the pandemic.
- The Company had made relevant disclosures to stock exchanges on 8th June 2020 under SEBI Circular dated November 26, 2018 as applicable to Large Corporate Borrowers.
- The proceedings initiated against Imperial Hospitals and Research Centre Limited, a subsidiary company, by the Government of Karnataka alleging, non-compliance of certain conditions associated with the allotment of land, has been stayed by the Honorable High Court of Karnataka on April 27, 2018. Based on legal opinion, the management is of the opinion that it has adequate grounds to demonstrate compliance with applicable conditions and therefore the proceedings are not sustainable. There have been no further developments during this quarter.

16. Standalone :-

Effective April 1, 2019, the Company adopted Ind AS 116 "Leases", applied to all lease contracts existing as on the said date, using the modified retrospective method and modified prospective method. For leases where modified retrospective method was applied, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019. On transition to Ind AS 116, the Company recognised right-of-use assets amounting to Rs.1,21,238 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs.1,42,713 lakhs and Rs. 21,094 lakhs (debit) in retained earnings (net of deferred tax) as at April 1, 2019. The Company has recognized interest expense on lease liabilities amounting to Rs. 3,283 lakhs & Rs.12,732 lakhs and depreciation on right-of-use asset amounting to Rs. 4,196 lakhs and Rs. 15,353 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs.1,419 lakhs and Rs.5,504 lakhs for the three months and year ended March 31, 2020 respectively.

Consolidated:-

Effective April 1, 2019, the Group adopted Ind AS 116 "Leases", applied to all lease contracts existing as on the said date, using the modified retrospective method and modified prospective method. For leases where modified retrospective method was applied, the cumulative effect of initial application is recognised in retained earnings at April 1, 2019. On transition to Ind AS 116, the Group recognised right-of-use assets amounting to Rs.1,60,578 lakhs (net of related accumulated depreciation), lease liabilities amounting to Rs. 191,313 lakhs and Rs. 26,990 lakhs (debit) in retained earnings (net of deferred tax) as at April 1, 2019. The Group has discounted lease payments using the applicable incremental borrowing rate as at April 1, 2019 for measuring the lease liability. During the three months and year ended March 31, 2020, the Group has recognized interest expense on lease liabilities amounting to Rs. 4,434 lakhs & Rs. 17,038 lakhs and depreciation on right-of-use asset amounting to Rs. 5,363 lakhs and Rs. 20,047 lakhs respectively. The effect of applying this standard resulted in reduction of profit by Rs. 1,676 lakhs and Rs. 7,161 lakhs for the three months and year ended March 31, 2020, respectively.

Place : Chennai

Date : 25th June 2020

For Apollo Hospitals Enterprise Limited,

DR. PRATHAP C REDDY

Executive Chairman

மக்கள் கரல்

நடுநிலை நாளேடு



காவலர்களின் பக்கி.

Makkal kural 27-Jun-20 Chennai Pages

BREAKING NEWS செய்யப்பட்ட காவலர் முத்தராஜ் 17-ந்தேதி வன

Page 03



தமிழகத்தில் கோரோனா தொற்று பரந்தவர்களுக்கு விலை உயர்ந்த, வீரியமிக்க மருந்துகளை கொண்டு சிகிச்சை: அமைச்சர் விஜயபாஸ்கர் தகவல்



விஜயபாஸ்கர், 27-6-2020
தமிழகத்தில் கோரோனா தொற்று பரந்தவர்களுக்கு விலை உயர்ந்த, வீரியமிக்க மருந்துகளை கொண்டு சிகிச்சை: அமைச்சர் விஜயபாஸ்கர் தகவல்

அமைச்சர் விஜயபாஸ்கர், 27-6-2020
தமிழகத்தில் கோரோனா தொற்று பரந்தவர்களுக்கு விலை உயர்ந்த, வீரியமிக்க மருந்துகளை கொண்டு சிகிச்சை: அமைச்சர் விஜயபாஸ்கர் தகவல்

27-6-2020 3

கோரோனாவிற்கு மருந்து கிடைக்காத நிலை
கோரோனாவிற்கு மருந்து கிடைக்காத நிலை

அக்கறை கொள்கிறோம்

idea

சென்னை, 27-6-2020

காவலர் வளர் பங்குதாரத்திற்கு

விருதுவேலி காவலர்

காவலர் வளர் பங்குதாரத்திற்கு

விருதுவேலி காவலர்

காவலர் வளர் பங்குதாரத்திற்கு

விருதுவேலி காவலர்

Apollo Hospitals Enterprise Limited

Corporate Identity Number: L851 017191915000
 Regd. Office: No. 10-B, 10-C, 10-D, 10-E, 10-F, 10-G, 10-H, 10-I, 10-J, 10-K, 10-L, 10-M, 10-N, 10-O, 10-P, 10-Q, 10-R, 10-S, 10-T, 10-U, 10-V, 10-W, 10-X, 10-Y, 10-Z, 10-AA, 10-AB, 10-AC, 10-AD, 10-AE, 10-AF, 10-AG, 10-AH, 10-AI, 10-AJ, 10-AL, 10-AM, 10-AN, 10-AO, 10-AP, 10-AQ, 10-AR, 10-AS, 10-AT, 10-AU, 10-AV, 10-AW, 10-AX, 10-AY, 10-AZ, 10-BA, 10-BB, 10-BC, 10-BD, 10-BE, 10-BF, 10-BG, 10-BH, 10-BI, 10-BJ, 10-BL, 10-BM, 10-BN, 10-BO, 10-BP, 10-BQ, 10-BR, 10-BS, 10-BT, 10-BU, 10-BV, 10-BW, 10-BX, 10-BY, 10-BZ, 10-CA, 10-CB, 10-CC, 10-CD, 10-CE, 10-CF, 10-CG, 10-CH, 10-CI, 10-CJ, 10-CL, 10-CM, 10-CN, 10-CO, 10-CP, 10-CQ, 10-CR, 10-CS, 10-CT, 10-CU, 10-CV, 10-CW, 10-CX, 10-CY, 10-CZ, 10-DA, 10-DB, 10-DC, 10-DD, 10-DE, 10-DF, 10-DG, 10-DH, 10-DI, 10-DJ, 10-DL, 10-DM, 10-DN, 10-DO, 10-DP, 10-DQ, 10-DR, 10-DS, 10-DT, 10-DU, 10-DV, 10-DW, 10-DX, 10-DY, 10-DZ, 10-EA, 10-EB, 10-EC, 10-ED, 10-EE, 10-EF, 10-EG, 10-EH, 10-EI, 10-EJ, 10-EL, 10-EM, 10-EN, 10-EO, 10-EP, 10-EQ, 10-ER, 10-ES, 10-ET, 10-EU, 10-EV, 10-EW, 10-EX, 10-EY, 10-EZ, 10-FA, 10-FB, 10-FC, 10-FD, 10-FE, 10-FG, 10-FH, 10-FI, 10-FJ, 10-FL, 10-FM, 10-FN, 10-FO, 10-FP, 10-FQ, 10-FR, 10-FS, 10-FT, 10-FU, 10-FV, 10-FW, 10-FX, 10-FY, 10-FZ, 10-GA, 10-GB, 10-GC, 10-GD, 10-GE, 10-GF, 10-GG, 10-GH, 10-GI, 10-GJ, 10-GL, 10-GM, 10-GN, 10-GO, 10-GP, 10-GQ, 10-GR, 10-GS, 10-GT, 10-GU, 10-GV, 10-GW, 10-GX, 10-GY, 10-GZ, 10-HA, 10-HB, 10-HC, 10-HD, 10-HE, 10-HF, 10-HG, 10-HI, 10-HJ, 10-HL, 10-HM, 10-HN, 10-HO, 10-HP, 10-HQ, 10-HR, 10-HS, 10-HT, 10-HU, 10-HV, 10-HW, 10-HX, 10-HY, 10-HZ, 10-IA, 10-IB, 10-IC, 10-ID, 10-IE, 10-IF, 10-IG, 10-IH, 10-II, 10-IL, 10-IM, 10-IN, 10-IO, 10-IP, 10-IQ, 10-IR, 10-IS, 10-IT, 10-IU, 10-IV, 10-IW, 10-IX, 10-IY, 10-IZ, 10-JA, 10-JB, 10-JC, 10-JD, 10-JE, 10-JF, 10-JG, 10-JH, 10-JI, 10-JJ, 10-JL, 10-JM, 10-JN, 10-JO, 10-JP, 10-JQ, 10-JR, 10-JS, 10-JT, 10-JU, 10-JV, 10-JW, 10-JX, 10-JY, 10-JZ, 10-KA, 10-KB, 10-KC, 10-KD, 10-KE, 10-KF, 10-KG, 10-KH, 10-KI, 10-KJ, 10-KL, 10-KM, 10-KN, 10-KO, 10-KP, 10-KQ, 10-KR, 10-KS, 10-KT, 10-KU, 10-KV, 10-KW, 10-KX, 10-KY, 10-KZ, 10-LA, 10-LB, 10-LC, 10-LD, 10-LE, 10-LF, 10-LG, 10-LH, 10-LI, 10-LJ, 10-LK, 10-LM, 10-LN, 10-LO, 10-LP, 10-LQ, 10-LR, 10-LS, 10-LT, 10-LU, 10-LV, 10-LW, 10-LX, 10-LY, 10-LZ, 10-MA, 10-MB, 10-MC, 10-MD, 10-ME, 10-MF, 10-MG, 10-MH, 10-MI, 10-MJ, 10-MK, 10-ML, 10-MN, 10-MO, 10-MP, 10-MQ, 10-MR, 10-MS, 10-MT, 10-MU, 10-MV, 10-MW, 10-MX, 10-MY, 10-MZ, 10-NA, 10-NB, 10-NC, 10-ND, 10-NE, 10-NF, 10-NG, 10-NH, 10-NI, 10-NJ, 10-NK, 10-NL, 10-NM, 10-NO, 10-NP, 10-NQ, 10-NR, 10-NS, 10-NT, 10-NU, 10-NV, 10-NW, 10-NX, 10-NY, 10-NZ, 10-OA, 10-OB, 10-OC, 10-OD, 10-OE, 10-OF, 10-OG, 10-OH, 10-OI, 10-OJ, 10-OK, 10-OL, 10-OM, 10-ON, 10-OO, 10-OP, 10-OQ, 10-OR, 10-OS, 10-OT, 10-OU, 10-OV, 10-OW, 10-OX, 10-OY, 10-OZ, 10-PA, 10-PB, 10-PC, 10-PD, 10-PE, 10-PF, 10-PG, 10-PH, 10-PI, 10-PJ, 10-PK, 10-PL, 10-PM, 10-PN, 10-PO, 10-PP, 10-PQ, 10-PR, 10-PS, 10-PT, 10-PU, 10-PV, 10-PW, 10-PX, 10-PY, 10-PZ, 10-QA, 10-QB, 10-QC, 10-QD, 10-QE, 10-QF, 10-QG, 10-QH, 10-QI, 10-QJ, 10-QL, 10-QM, 10-QN, 10-QO, 10-QP, 10-QQ, 10-QR, 10-QS, 10-QT, 10-QU, 10-QV, 10-QW, 10-QX, 10-QY, 10-QZ, 10-RA, 10-RB, 10-RC, 10-RD, 10-RE, 10-RF, 10-RG, 10-RH, 10-RI, 10-RJ, 10-RK, 10-RL, 10-RM, 10-RN, 10-RO, 10-RP, 10-RQ, 10-RR, 10-RS, 10-RT, 10-RU, 10-RV, 10-RW, 10-RX, 10-RY, 10-RZ, 10-SA, 10-SB, 10-SC, 10-SD, 10-SE, 10-SF, 10-SG, 10-SH, 10-SI, 10-SJ, 10-SK, 10-SL, 10-SM, 10-SN, 10-SO, 10-SP, 10-SQ, 10-SR, 10-SS, 10-ST, 10-SU, 10-SV, 10-SW, 10-SX, 10-SY, 10-SZ, 10-TA, 10-TB, 10-TC, 10-TD, 10-TE, 10-TF, 10-TG, 10-TH, 10-TI, 10-TJ, 10-TK, 10-TL, 10-TM, 10-TN, 10-TO, 10-TP, 10-TQ, 10-TR, 10-TS, 10-TT, 10-TU, 10-TV, 10-TW, 10-TX, 10-TY, 10-TZ, 10-UA, 10-UB, 10-UC, 10-UD, 10-UE, 10-UF, 10-UG, 10-UH, 10-UI, 10-UJ, 10-UK, 10-UL, 10-UM, 10-UN, 10-UO, 10-UP, 10-UQ, 10-UR, 10-US, 10-UT,

VGN STAFFORD
Because, you deserve a better life.
HOMES NEAR AMBATTUR

குடியேறத் தயார் நிலையில் வீடுகள்.

42,000 sq. ft. க்கு மேல்
கனம் தரம் வசதிகள்
உட்பட பல்வேறு வசதிகள்.

9 கி.மீ. தொலைவில் அண்ணா நகர்

2 & 3 BHK வீடுகள்
1159 முதல் 1545 சதுர அடி வரை

VGN
CREATING ASSETS SINCE 1942

CALL: 44-4343 9999